Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 26, 2024; 12(9): 1569-1577
Published online Mar 26, 2024. doi: 10.12998/wjcc.v12.i9.1569
Efficacy and safety of minimally invasive laparoscopic surgery under general anesthesia for ovarian cancer
Xian Qin, Chen Chen, Yang Liu, Xian-Hong Hua, Jia-Yi Li, Meng-Jie Liang, Fang Wu
Xian Qin, Chen Chen, Yang Liu, Xian-Hong Hua, Department of Anesthesiology, The First People's Hospital of Jiangxia District, Wuhan 430200, Hubei Province, China
Jia-Yi Li, Meng-Jie Liang, Fang Wu, Department of Obstetrics and Gynecology, The First People's Hospital of Jiangxia District, Wuhan 430200, Hubei Province, China
Co-first authors: Xian Qin and Chen Chen.
Author contributions: Qin Xand Chen C designed the research; Liu Y, Hua XH, Li JY and Liang MJ contributed new reagents/analytic tools; Qin X and Chen C analyzed the data; Wu F, Qin X and Chen C wrote the paper; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript; Qin X and Chen C contributed equally to this work as co-first authors equally to this work. The reasons for designating Qin X and Chen C as co-first authors are threefold. First, Data analysis: All two authors analyzed or explained the data of the article; second, Design and implementation of the experiment: All two authors participated in the design and implementation of the experiment; third, Data interpretation: All two authors have made important contributions to data interpretation.
Institutional review board statement: This study protocol was approved by the institutional review boards of The First People's Hospital of Jiangxia District.
Informed consent statement: All the families have voluntarily participated in the study and have signed informed consent forms.
Conflict-of-interest statement: The authors declared no conflict of interest existing in this paper.
Data sharing statement: Data generated from this investigation are available upon reasonable quest from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Wu, MBChB, Department of Obstetrics and Gynecology, The First People's Hospital of Jiangxia District, No. 1 Zhifang Cultural Avenue, Jiangxia District, Wuhan 430200, Hubei Province, China. wufang771025@163.com
Received: November 30, 2023
Peer-review started: November 30, 2023
First decision: December 18, 2023
Revised: January 4, 2024
Accepted: February 28, 2024
Article in press: February 28, 2024
Published online: March 26, 2024
Abstract
BACKGROUND

Ovarian cancer is one of the most common malignant tumors in female reproductive system in the world, and the choice of its treatment is very important for the survival rate and prognosis of patients. Traditional open surgery is the main treatment for ovarian cancer, but it has the disadvantages of big trauma and slow recovery. With the continuous development of minimally invasive technology, minimally invasive laparoscopic surgery under general anesthesia has been gradually applied to the treatment of ovarian cancer because of its advantages of less trauma and quick recovery. However, the efficacy and safety of minimally invasive laparoscopic surgery under general anesthesia in the treatment of ovarian cancer are still controversial.

AIM

To explore the efficacy and safety of general anesthesia minimally invasive surgery in the treatment of ovarian cancer.

METHODS

The clinical data of 90 patients with early ovarian cancer in our hospital were analyzed retrospectively. According to the different surgical treatment methods, patients were divided into study group and control group (45 cases in each group). The study group received minimally invasive laparoscopic surgery under general anesthesia for ovarian cancer, while the control group received traditional open surgery for ovarian cancer. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), clinical efficacy and safety of the two groups were compared.

RESULTS

The intraoperative blood loss, length of hospital stay, postoperative gas evacuation time, and postoperative EORTC QLQ-C30 score of the study group were significantly better than those of the control group (P < 0.05). The incidence of postoperative complications in the study group was significantly lower than in the control group (P < 0.05). The two groups had no significant differences in the preoperative adrenocorticotropic hormone (ACTH), androstenedione (AD), cortisol (Cor), cluster of differentiation 3 positive (CD3+), and cluster of differentiation 4 positive (CD4+) indexes (P > 0.05). In contrast, postoperatively, the study group's ACTH, AD, and Cor indexes were lower, and the CD3+ and CD4+ indexes were higher than those in the control group (P < 0.05).

CONCLUSION

Minimally invasive laparoscopic surgery under general anesthesia in patients with early ovarian cancer can significantly improve the efficacy and safety, improve the short-term prognosis and quality of life of patients, and is worth popularizing.

Keywords: Early-stage ovarian cancer, Efficacy, Minimally invasive, Laparoscopy, Safety, Surgery

Core Tip: This study found that compared with traditional open surgery, minimally invasive laparoscopic surgery under general anesthesia has better curative effect, faster recovery speed, lower risk of complications and less impact on immune function in the treatment of patients with early ovarian cancer. Therefore, minimally invasive laparoscopic surgery under general anesthesia can be the first choice for patients with early ovarian cancer.